More importantly, the lowest frequencies of other treatment-related adverse effects (TRAEs) were observed in the group of furmonertinib, including skin rash, leucopenia, thrombocytopenia, anemia, interstitial lung disease (ILD), and creatine phosphokinase (CPK) elevation. Here, PIK3C2A is linked to interstitial lung disease.